Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
Streamlined Hyeracute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression is Stroke Mimic
Stroke 47:1012-1017, Goyal, M.S.,et al, 2016
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Arch Neurol 65:1429-1433, Liang,B.A.,et al, 2008
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006